Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coherus Oncology (CHRS) Revenue (2016 - 2025)

Historic Revenue for Coherus Oncology (CHRS) over the last 12 years, with Q3 2025 value amounting to $11.6 million.

  • Coherus Oncology's Revenue rose 9119.3% to $11.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $277.7 million, marking a year-over-year increase of 15206.75%. This contributed to the annual value of $267.0 million for FY2024, which is 377.7% up from last year.
  • According to the latest figures from Q3 2025, Coherus Oncology's Revenue is $11.6 million, which was up 9119.3% from $10.3 million recorded in Q2 2025.
  • In the past 5 years, Coherus Oncology's Revenue registered a high of $248.3 million during Q4 2024, and its lowest value of $2.3 million during Q1 2024.
  • In the last 5 years, Coherus Oncology's Revenue had a median value of $58.7 million in 2023 and averaged $57.4 million.
  • Its Revenue has fluctuated over the past 5 years, first tumbled by 9288.44% in 2024, then surged by 22924.61% in 2025.
  • Over the past 5 years, Coherus Oncology's Revenue (Quarter) stood at $73.4 million in 2021, then crashed by 38.17% to $45.4 million in 2022, then surged by 101.81% to $91.5 million in 2023, then soared by 171.3% to $248.3 million in 2024, then plummeted by 95.34% to $11.6 million in 2025.
  • Its Revenue stands at $11.6 million for Q3 2025, versus $10.3 million for Q2 2025 and $7.6 million for Q1 2025.